



**Seasoned medical device company boss,  
Mark Harwood joins Camstent as CEO**

**2 July 2019** – Camstent Ltd., the company applying proprietary bacteria-phobic polymer coatings to medical devices, announces the appointment of Mark Harwood as CEO. Mark is a highly respected figure with an exceptional track record in the medical device sector.

Mark is returning to the UK from Malaysia where he spent two and a half years undertaking consultancy and M&A projects with healthcare businesses in the region. This included transforming a family-run emergency services business into a mid-sized corporation. In the UK, Mark is best known for his time as CEO of PneumaCare, the Cambridge UK-based respiratory monitoring medical imaging company. Here, he developed a range of respiratory products, conducted global clinical studies, published numerous papers and significantly expanded the company's distribution network and sales.

Mark spent a number of years in the US in leading roles in medical device companies including President and CEO of ArjoHuntleigh in Roselle, US, Vice President of Baxter International Inc. (Global) based in Chicago, IL, US, and President of RF Technologies (North America & EMEA) based in Brookfield WI, US. Prior to this Mark was based in Gloucester as Managing Director for Arjo Med AB, UK & Ireland.

Camstent's founder and COO, Dave Hampton, said: "We are extremely fortunate to have Mark join us as Chief Executive Officer. His arrival comes at a critical time for Camstent and the Board believes he will play a pivotal role in the company's next stage of development. Mark has an outstanding track record of growing small medical device companies into global players as well as managing large teams where he oversees all aspects of a business including sales, marketing and manufacturing. He also has extensive regulatory and quality experience which will be key for us as we look to expand our sales into the US, a market where he has a considerable knowledge."

Mark Harwood said: "I am very excited to be joining Camstent and returning to the UK once again. Camstent's bacteria-phobic coatings have the potential to become real game-changers in the battle against infections caused by medical devices. I am looking forward to working with the team, to grow the company sales and increase awareness of the Camstent's products in core markets, both in the UK and overseas."



NOTES TO EDITORS:

Camstent Ltd.

Dr Dave Hampton, Chief Operating Officer [info@camstent.com](mailto:info@camstent.com)

+44 (0) 333 987 4050

Media enquiries, further information and photography:

Ariane Comstive [ariane@lodgehillcomms.co.uk](mailto:ariane@lodgehillcomms.co.uk)

+44 1935 852 174 / +44 7785 922 354

Julia Price [Julia@julaprice.co.uk](mailto:Julia@julaprice.co.uk)

+44 7737 864 878

**About Camstent**

Camstent's mission is to address the problem of hospital-acquired infections that affect 1 in 25 patients (300,000 people in England and 1.7 million in the US). Thirty-eight per cent of these are the result of catheter associated urinary infections, increasing patient morbidity and length of hospital stays. In the US, as many as 99,000 patients die from these infections every year; 37,000 in Europe and almost 10,000 in the UK. After extensive development by Camstent, the bacteria-phobic polymers, which were first discovered at the University of Nottingham in 2012, have been formulated as a coating for catheters and other silicon/silastic medical devices.

Camstent [bacteria-phobic] coated catheters are [ISO 13485 certified and] CE marked for drainage of urine and enhanced lubricity [and is currently undergoing a Notified Body review for this bacteria-phobic claim extension]. They are available for sale in the UK and EU.

- Ends -